Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Slides:

Advertisements

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:

Advertisements

Baseline Characteristics According to CET Rate Marianne Zeller, et al. J Am Coll Cardiol 2007;50:

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]

Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Quartiles of complete blood count components Jeffrey L. Anderson, et al. Am J Cardiol 2007;99:

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.

Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );

Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Date of download: 7/14/2016 Copyright © The American College of Cardiology. All rights reserved. From: Thoracic Aortic Aneurysm and Dissection J Am Coll.

From: Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Implantation J Am Coll.

JAMA. 2014;312(2): doi: /jama Figure Legend:

Baseline Characteristics of the Patients Part I

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Trial profile John A Dormandy et al. Lancet 2005;366:

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Jun M, et al. Lancet 2010 Epub May 10

Figure 4 TAVI for bicuspid aortic valve disease

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

End point Fenoldopam, n (%) Dopamine, n (%) p

Johannes Steiner et al. JACC 2017;70:

Nat. Rev. Cardiol. doi: /nrcardio

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Change in symptoms in operated and unoperated patients 1 year following evaluation of surgical AVR. Pie charts display change from baseline to follow-up.

Efficacy and safety of niacin/laropiprant

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Patient characteristics in the entire study group

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Nicolaj C. Hansson et al. JACC 2016;68:

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Baseline Characteristics of the Subjects

Flow of Patients Through the Trial

Baseline Characteristics of the Study Participants

Baseline Clinical Characteristics

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Disposition of Patients in the Atherogenic Dyslipidemia Study

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Baseline Characteristics by hs-CRP

Distribution of relative percentage change ((post-AVR−pre-AVR)/pre-AVR) in the patients’ absolute pVO2 values between pre-AVR and post-AVR after 9 months.

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.

Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Baseline characteristics of study population

Demographic Characteristics of Patients Treated With Statins Versus Those Not Treated With Statins Goldberger JJ, et al. J Am Coll Cardiol 2006;48:

Maxime Berthelot-Richer et al. JIMG 2016;9:

Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

PHOENIX I: PASI 75 Response After 12 Weeks

A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic imaging for patient A–J, Pretreatment (A) and post–cycle 3 (B) computed tomographic.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Presentation transcript:

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic

Baseline characteristics of patients Dichtl W, et al. Am J Cardiol. 2008;102:743-8

Kaplan-Meier curves Dichtl W, et al. Am J Cardiol. 2008;102:743-8

Multivariate regression analysis predicting major adverse clinical events Dichtl W, et al. Am J Cardiol. 2008;102:743-8

Kaplan-Meier curves Dichtl W, et al. Am J Cardiol. 2008;102:743-8

Effects of atorvastatin treatment (n = 19) versus placebo (n = 16) Dichtl W, et al. Am J Cardiol. 2008;102:743-8

Changes in patients treated with atorvastatin therapy or placebo Dichtl W, et al. Am J Cardiol. 2008;102:743-8